Gowrishankar Banumathy, Ibragimova Ilsiya, Zhou Yan, Slifker Michael J, Devarajan Karthik, Al-Saleem Tahseen, Uzzo Robert G, Cairns Paul
Cancer Epigenetics Program; Fox Chase Cancer Center; Philadelphia, PA USA.
Biostatistics and Bioinformatics; Fox Chase Cancer Center; Philadelphia, PA USA.
Cancer Biol Ther. 2014 Mar 1;15(3):329-41. doi: 10.4161/cbt.27314. Epub 2013 Dec 18.
Clear cell RCC is the most common, and more likely to metastasize, of the three main histological types of RCC. Pathologic stage is the most important prognostic indicator and nuclear grade can predict outcome within stages of localized RCC. Epithelial tumors are thought to accumulate a series of genetic and epigenetic changes as they progress through well-defined clinical and histopathological changes. MicroRNAs (miRNAs) are involved in the regulation of mRNA expression from many human genes and miRNA expression is dysregulated in cancer. To better understand the contribution of dysregulated miRNA expression to the progression and biology of ccRCC, we examined the differences in expression levels of 723 human miRNAs through a series of analyses by stage, grade, and disease progression status in a large series of 94 ccRCC. We found a consistent signature that included significant upregulation of miR-21-5p, 142-3p, let-7g-5p, let-7i-5p and 424-5p, as well as downregulation of miR-204-5p, to be associated with ccRCC of high stage, or high grade, or progression. Discrete signatures associated with each of stage, grade, or progression were also identified. The let-7 family was significantly downregulated in ccRCC compared with normal renal parenchyma. Expression of the 6 most significantly differentially expressed miRNAs between ccRCC was verified by stem-loop qRT-PCR. Pathways predicted as targets of the most significantly dysregulated miRNAs included signaling, epithelial cancers, metabolism, and epithelial to mesenchymal transition. Our studies help to further elucidate the biology underlying the progression of ccRCC and identify miRNAs for potential translational application.
透明细胞肾细胞癌是肾细胞癌三种主要组织学类型中最常见且更易发生转移的类型。病理分期是最重要的预后指标,核分级可预测局限性肾细胞癌各期的预后。上皮性肿瘤在经历明确的临床和组织病理学变化过程中,被认为会积累一系列基因和表观遗传变化。微小RNA(miRNA)参与许多人类基因的mRNA表达调控,且miRNA表达在癌症中失调。为了更好地理解失调的miRNA表达对透明细胞肾细胞癌进展和生物学特性的作用,我们通过对94例透明细胞肾细胞癌的分期、分级和疾病进展状态进行一系列分析,检测了723种人类miRNA的表达水平差异。我们发现了一个一致的特征,包括miR-21-5p、142-3p、let-7g-5p、let-7i-5p和424-5p的显著上调,以及miR-204-5p的下调,这些与高分期、高分级或进展期的透明细胞肾细胞癌相关。还确定了与分期、分级或进展各自相关的离散特征。与正常肾实质相比,透明细胞肾细胞癌中let-7家族显著下调。通过茎环定量逆转录聚合酶链反应验证了透明细胞肾细胞癌中6种差异最显著的miRNA的表达。预测为失调最显著的miRNA靶标的通路包括信号传导、上皮性癌、代谢和上皮-间质转化。我们的研究有助于进一步阐明透明细胞肾细胞癌进展的生物学机制,并鉴定出有潜在转化应用价值的miRNA。